Objective: Human neural precursor cell-expressed developmentally down-regulated 4 like (Nedd4L), a ubiquitin protein ligase, is expressed by various cancer cells and might have an oncogenic property. Its expression pattern in glioma tissues is unknown. Therefore, the aim of this study was to investigate whether Nedd4L is present in glioma and to evaluate the correlation of Nedd4L expression with the progression and prognosis of the disease. Methods: Immunohistochemistry and western blot were used to investigate the expression of Nedd4L protein in 128 patients with gliomas. Results: Immunohistochemistry showed a strong-to-weak range of Nedd4L staining with increasing pathologic grade of glioma (P , 0.001), which was in line with the results from western blot analysis. In addition, a non-parametric analysis revealed that the attenuated Nedd4L expression was significantly correlated with a large tumor diameter (P ¼ 0.02), low Karnofsky performance score (P ¼ 0.008), frequent intra-tumor necrosis (P ¼ 0.01) and worse overall survival (P ¼ 0.009). Furthermore, multivariate analysis showed that Nedd4L expression (P ¼ 0.02) and intra-tumor necrosis (P ¼ 0.03) were two important independent prognostic factors identified by the Cox proportional hazards model. Conclusions: Our results provide convincing evidence for the first time that the expression of Nedd4L is down-regulated in human gliomas. The glioma patients with lower Nedd4L expression have a worse prognosis.
INTRODUCTION
Glioma, as the most common primary brain tumors in adult humans, continues to be the cause of a disproportionate level of morbidity and mortality across a wide range of individuals. The key features of this disease are local invasive growth and strong angiogenesis. Gliomas are histologically classified into four grades (Grades I -IV), according to the World Health Organization (WHO) guidelines (1) . Grade IV glioma, glioblastoma, has the worst prognosis even after surgical resection, radiation therapy and chemotherapy (2) . Numerous studies have showed that age, performance status, histologic grade and tumor necrosis are important prognostic factors for gliomas. However, these clinical parameters do not fully account for the observed variation in survival rates and the prognosis of both high-and low-grade tumors remains heterogeneous (3) . Therefore, additional indicators are needed to more accurately determine the prognosis of patients with gliomas.
The neural precursor cell-expressed developmentally down-regulated 4-like (Nedd4L) gene encodes a ubiquitin ligase that targets the epithelial sodium channel (ENaC) for degradation (4) . It participates in the regulation of plasma volume and blood pressure by controlling expression of ENaC which is a heteromultimeric protein complex. The ubiquitination of ENaC is catalyzed by Nedd4L, initiating ubiquitin-mediated endocytosis and lysosomal targeting of ENaC for its removal from the luminal cell membrane in renal collecting ducts (5) . Recent studies have demonstrated that Nedd4L targets a broad range of molecules along with ENaC and is thus thought to be involved in various biological properties other than regulating ion channels (6) . Human Nedd4L is a homologue of the mouse Nedd4-2, which was identified as a novel protein which could inhibit transforming growth factor b (TGF-b) signaling in TGF-b receptors and Smads levels (7) . It has been reported that TGF-b signaling is involved in a variety of biological processes, including regulation of cell growth, angiogenesis, immune response and modulation of extracellular matrix (8) . In gliomas, previous studies have indicated that TGF-b signaling plays an important role in the pathobiology of invasion of the tumor (9) . Therefore, investigation into the TGF-b system in glioma is needed in order to learn whether there are candidate prognostic markers in this system can be manipulated for survival prediction of gliomas. Nedd4L has been detected in various cancer cells and might have an oncogenic property. However, its expression pattern in glioma tissues is unknown. Therefore, the aim of this study was to investigate whether Nedd4L is present in glioma and to evaluate the correlation of Nedd4L expression with the progression and prognosis of the disease. Table 1 . Paraffin and snap-frozen sections of non-neoplastic brain tissues from 10 patients with intractable epilepsy were also included as controls. A 5-year follow-up was performed, and all patients had a complete follow-up until death. The overall survival time was calculated from the date of the initial surgical operation to death. Patients, who died of diseases not directly related to their gliomas, or due to unexpected events, were excluded from this study. In addition, 20 glioma specimens [5 pilocytic astrocytomas (WHO I), 3 diffuse astrocytomas (WHO II), 3 anaplasia astrocytomas (WHO III) and 9 primary glioblastomas (WHO IV)] were snap frozen in liquid nitrogen and stored at 2808C following surgery for analysis by western blot analysis.
PATIENTS AND METHODS

PATIENTS AND TISSUE SAMPLES
IMMUNOHISTOCHEMISTRY ASSAY
Formalin-fixed, paraffin-embedded, sectioned tissues (4 mm thick) were immunostained using the Labelled Streptavidin Biotin 2 System (BioGenex; San Ramon, CA, USA). Following peroxidase blocking with 0.3% H 2 O 2 /methanol for 30 min, specimens were blocked with phosphate-buffered saline (PBS) containing 5% normal horse serum (Vector Laboratories Inc., Burlingame, CA, USA). All incubations with a monoclonal antibody against human Nedd4L (HPA024618, Sigma-Aldrich, St Louis, MO, USA) at 1:10 dilution were carried out overnight at 48C. Then, the 
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specimens were briefly washed in PBS and incubated at room temperature with the anti-rabbit antibody and avidinbiotin peroxidase (Vector Laboratories Inc.). The specimens were then washed in PBS and color-developed by diaminobenzidine solution (Dako Corporation, Carpinteria, CA, USA). After washing with water, specimens were counterstained with Meyer's hematoxylin (Sigma Chemical Co., St Louis, MO, USA). Non-neoplastic brain tissues were used as control tissues and non-immune IgG was also used as a negative control antibody for immunohistochemical staining. Assessment of immunohistochemical staining was evaluated by two independent pathologists. The scores of the two pathologists were compared and any discrepant scores were trained through re-examining the stainings by both pathologists to achieve a consensus score. Expression of Nedd4L was compared between malignant glioma tissues and nonneoplastic brain tissues. The number of positive-staining cells showing immunoreactivity on the cytoplasm for Nedd4L in 10 representative microscopic fields was counted and the percentage of positive cells was calculated. The percentage scoring of immunoreactive tumor cells was as follows: 0 (0%), 1 (1 -10%), 2 (11 -50%) and 3 (.50%). The staining intensity was visually scored and stratified as follows: 0 (negative), 1 (weak), 2 (moderate) and 3 (strong). A final immunoreactivity score (IRS) was obtained for each case by multiplying the percentage and the intensity score.
WESTERN BLOT ANALYSIS
Twenty glioma and 10 non-neoplastic brain tissues were homogenized in lysis buffer [PBS, 1% Nonidet P-40, 0.5% sodium deoxycholate, 0.1% sodium dodecyl sulfate (SDS), 100 mg/ml aprotinin, 100 mg/ml phenylmethylsulfonyl fluoride (PMSF) and sodium orthovanadate] at 48C throughout all procedures and sonicated for 70 s, and then add 300 mg PMSF per gram of tissue and incubate on ice for 30 min, followed by centrifugation at 15 000 rpm for 20 min at 48C. The protein content was determined according to the Bradford method (Bradford 1976), with bovine serum albumin used as a standard. Equal amounts of protein were separated electrophoretically on 7.5% SDS -polyacrylamide gels and transferred onto polyvinylidene difluoride membranes (Roche, Basel, Switzerland). The membranes were probed with an anti-Nedd4L rabbit monoclonal antibody (1:250 dilution, HPA024618, Sigma-Aldrich). The expression level of Nedd4L was determined by incubating the membranes with horseradish peroxidase-conjugated antirabbit immunoglobulin G (1:3000 dilution) and enhanced chemiluminescence reagent (Pierce, Minneapolis, MN, USA), according to the manufacturer's suggested protocols. The membranes were stripped and reprobed with an anti-b-actin mouse monoclonal antibody (1:1000 dilution; Sigma, St Louis, MO, USA) as a loading control. Densitometry was performed using ImageJ software (http ://rsb.info.nih.gov/ij/) from National Institutes of Health (NIH, Bethesda, MD, USA). We evaluated the expression of Nedd4L as an optical densitometry ratio that was scored as the densitometry of Nedd4L relative to the densitometry of b-actin.
STATISTICAL ANALYSIS
All computations were carried out using the software of SPSS version 13.0 for Windows (SPSS Inc., IL, USA). Data were expressed as means + standard deviation. The amount of Nedd4L in positively expressed tissue samples was presented as a percentage (opacity density value of Nedd4L divided by the opacity density of the internal reference from b-actin as control). Statistical differences between the levels of Nedd4L expression in pathological grades were evaluated by the non-parametric Kruskal -Wallis test, and those differences in the bi-nominal clinical categories were evaluated by the non-parametric Mann -Whitney test. A life table was calculated according to the Kaplan -Meier method. Hazard ratios for the time-to-event endpoint were estimated using the multivariate Cox regression analysis in a forward stepwise method to evaluate the effect of multiple independent prognostic factors on survival outcome. Differences were considered statistically significant when P value was ,0.05.
RESULTS
DOWN-REGULATION OF NEDD4L PROTEIN IN HUMAN GLIOMA TISSUES
The protein expression of Nedd4L was detected by immunohistochemical staining in 10 normal brain tissues and 128 glioma specimens. In all gliomas, 59.38% (76/128) had weak staining and 40.62% (52/128) had moderate-to-strong staining. Immunoreactivity was also measured in six (60.00%) non-neoplastic brain samples, all of which had strong staining. Reduced expression of Nedd4L protein with cytoplasmic localization was observed in gliomas of different pathological grades when compared with normal brain tissue (Fig. 1) . The IRS of Nedd4L was 8.22 + 0.15 in nonneoplastic brain tissues, 6.16 + 0.21 in pilocytic astrocytomas (WHO I), 4.28 + 0.16 in diffuse astrocytomas (WHO II), 3.35 + 0.28 in anaplasia astrocytomas (WHO III) and 2.25 + 0.18 in glioblastomas (WHO IV). The median IRS value of Nedd4L in all the glioma samples was 4.01 + 0.19, which was significantly lower than that in non-neoplastic brain tissues (P , 0.001). Based on these results, we determined that gliomas with an IRS , 4 were more malignant and divided the glioma specimens into two categories (high score, IRS ! 4; low score, IRS , 4) for the survival analysis. Consistent with the IRS results, we found that the Nedd4L expression level was gradually decreased with tumor grades as assessed by western blot analysis (Fig. 2) . The Nedd4L/b-actin ratio was 1.21 + 0.35 in non-neoplastic brain specimens and significantly decreased in gliomas with increasing pathological grade (P , 0.001). The Nedd4L/ b-actin ratio was 0.66 + 0.28, 0.38 + 0.13, 0.26 + 0.11 and
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Down-regulation of Nedd4L in glioma 0.13 + 0.05 in pilocytic astrocytomas, diffuse astrocytomas, anaplasia astrocytomas and glioblastomas, respectively.
CORRELATION OF NEDD4L EXPRESSION WITH CLINICOPATHOLOGICAL FEATURES OF GLIOMAS
Nedd4L expression was much lower in more malignant gliomas than in less malignant gliomas (P , 0.001). The attenuated Nedd4L expression was significantly correlated with large tumor diameter (P ¼ 0.02), low Karnofsky performance score (KPS) (P ¼ 0.008) and frequent intra-tumor necrosis (P ¼ 0.01). In addition, no statistically significant correlation of Nedd4L with age at diagnosis and gender of patients was found (both P . 0.05).
CORRELATION OF NEDD4L EXPRESSION WITH OVERALL SURVIVAL IN PATIENTS WITH GLIOMAS
Spearman's rank correlation analysis showed that Nedd4L expression was significantly correlated with the overall survival of glioma patients (r ¼ 0.86, P ¼ 0.01). In addition, the Kruskal -Wallis test indicated that patients with IRS ! 4 for Nedd4L had longer overall survival than those patients with IRS , 4 of Nedd4L (20.1 + 0.9 vs. 11.5 + 0.4 months, respectively, P , 0.01). Survival curves for the two categories according to their pathological grades are shown in Fig. 3 . In multivariate analysis, the Cox proportional hazards model involving the IRS score of Nedd4L expression and various clinical parameters identified two prognostic variables including intra-tumor necrosis (P ¼ 0.03) and Nedd4L expression (P ¼ 0.02). Statistical values of the expression of Nedd4L and other clinical parameters derived from the Cox stepwise proportional hazards model are indicated in Table 2 .
DISCUSSION
To the best of our knowledge, this is the first study to demonstrate the correlation between Nedd4L and glioma. Our data from immunohistochemistry assay provided evidence that the Nedd4L protein expression is significantly reduced in glioma specimens than in their non-neoplastic counterpart, non-neoplastic brain tissues. In addition, reduced Nedd4L expression was correlated with increasing pathological grade of gliomas, underlining a connection between downregulation of Nedd4L and development of gliomas. This finding was consistent with the results of western blot analysis.
Ubiquitination serves multiple cellular functions, including proteasomal degradation and the control of stability, function and intracellular localization of a wide variety of proteins (10) . Nedd4L is a member of the HECT class of E3 ubiquitin ligases. Among various modulating proteins, Nedd4L binds the PY motif of ENaC COOH terminals and catalyzes ubiquitination of the NH(2) terminus of the protein for subsequent degradation. Both evolutionarily conserved and evolutionarily new C2 domains of human Nedd4L, a cryptic splice variant resulting in a disrupted isoform 200 Down-regulation of Nedd4L in glioma had better overall survival. In addition, Nedd4L expression and intra-tumor necrosis were two important independent prognostic factors identified by the Cox multivariate analysis. Age, gender, KPS, largest tumor diameter, extent of resection and type of adjuvant treatment did not reach statistical significance associated with survival.
In conclusion, our results provide convincing evidence for the first time that the expression of Nedd4L is downregulated in human gliomas. The glioma patients with lower Nedd4L expression have a worse prognosis.
